Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis

Journal of Clinical Immunology

Volumn 35, Issue 1, 2015, Pages 1-10

  Mortaz, Esmaeil ^a,b,c   Adcock, Ian M ^b   Tabarsi, Payam ^c   Masjedi, Mohammad Reza ^c   Mansouri, Davood ^d   Velayati, Ali Akbar ^c   Casanova, Jean Laurent ^e,f,g   Barnes, Peter J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ROCKEFELLER UNIVERSITY   (United States)

^f Inserm U1163   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

inflammasome; TLRs; Tuberculosis

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INFLAMMASOME; PATTERN RECOGNITION RECEPTOR; PENTRAXIN 3; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID P; TOLL LIKE RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MOUSE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANIMALS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; MICE; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; REACTIVE OXYGEN SPECIES; RECEPTORS, PATTERN RECOGNITION; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUBERCULOSIS;

EID: 84925814942     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-014-0103-7     Document Type: Article

References (131)

1. WHO Report—Global tuberculosis control. World Health Organization; Geneva: http://www.who.int/tb/publications/global_report/en/ (2013).
2. Incidence of tuberculosis (per 100,000 people) http://data.worldbank.org/indicator/SH.TBS.INCD.
3. Van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev. 2002;15:294–309.
4. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol. 2001;166:7033–41.
5. Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol. 2011;2011:814943.
6. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med. 1992;175(4):1111–22.
7. Van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol. 2000;30(12):3689–98.
8. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208(2):261–9.
9. Zhang M, Wang Z, Graner MW, Yang L, Liao M, Yang Q, et al. B cell infiltration is associated with the increased IL-17 and IL-22 expression in the lungs of patients with tuberculosis. Cell Immunol. 2011;270(2):217–23.
10. +T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–77.
11. Wozniak TM, Saunders BM, Ryan AA, Britton WJ. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun. 2010;78:4187–94.
12. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev. 2010;21(6):455–62.
13. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Crit Care Med. 2001;25:335–40.
14. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of Interleukin-17 receptor signalling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519–27.
15. Happel K, Dubin P, Zheng M, Ghilardi N, Lockhart C, Quinton L, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med. 2005;202:761–9.
16. Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence. 2010;1:423–7.
17. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med. 2003;35(3):226–35.
18. Andrade Jr DR, Souza RB, Santos SA, Andrade DR. Oxygen free radicals and pulmonary disease. J Bras Pneumol. 2005;31(1):60–8.
19. Mak JC. Pathogenesis of COPD. Part II. Oxidative-anti-oxidative imbalance. Int J Tuberc Lung Dis. 2008;12(4):368–74.
20. Hartmann P, Becker R, Franzen C, Schell-Frederick E, Romer J, Jacobs M, et al. Phagocytosis and killing of Mycobacterium avium complex by human neutrophils. J Leukocyte Biol. 2001;69:397.
21. Azfar SF, Islam N. Suppression of Mycobacterium tuberculosis induced reactive oxygen species and tumor necrosis factor-alpha activity in human monocytes of systemic lupus erythematosus patients by reduced glutathione. Oman Med J. 2012;27(1):11–9.
22. Zuñiga J, Torres-García D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EJ. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol. 2012;2012:193923.
23. Kumar A, Farhana A, Guidry L, Saini V, Hondalus M, Steyn AJ. Redox homeostasis in mycobacteria: the key to tuberculosis control? Expert Rev Mol Med. 2011;13:e39.
24. Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chapgier A, et al. BCG-osisandtuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007;120(1):32–8.
25. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000;97(16):8841–8.
26. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87(4):1620–4.
27. Montgomery LG, Lemon WS. The cellular reaction of the pleura to infection with Mycobacterium tuberculosis. J Thorac Cardiovasc Surg. 1993;2:429.
28. Gurumurthy M, Rao M, Mukherjee T, Rao SP, Boshoff HI, Dick T, et al. A novel F(420)—dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol. 2013;87(4):744–55.
29. Bryk R, Lima CD, Erdjument-Bromage H, Tempst P, Nathan C. Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science. 2002;295(5557):1073–7.
30. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–84.
31. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826–37.
32. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006;442:39–44.
33. Akira S, Uematsu S, Takeuchi O. Pathogen recognition andinnate immunity. Cell. 2006;12:783–801.
34. Cui S, Eisenacher K, Kirchhofer A, Brzozka K, Lammens A, Lammens K, et al. The C-terminal regulatory domain is the RNA 50 -triphosphate sensor of RIG-I. Mol Cell. 2008;29:169–79.
35. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–50.
36. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.
37. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447–91.
38. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782–7.
39. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–7.
40. Doyle SL, O’Neill LA. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol. 2006;72:1102–13.
41. Gan L, Li L. Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity. Immunol Res. 2006;35:295–302.
42. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85–95.
43. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398–401.
44. Kay E, Scotland RS, Whiteford JR. Toll-like receptors: role in inflammation and therapeutic potential. Biofactors. 2013. doi:10.1002/biof.1156.
45. Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2013;47(2):136–47.
46. Hossain MM, Norazmi MN. Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection-the double-edged sword. Biomed Res Int. 2013;2013:179174.
47. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–5.
48. Mortaz E, Adcock IM, Ito K, Kraneveld AD, Nijkamp FP, Folkerts G. Cigarette smoke induces CXCL8 production by human neutrophils via activation of TLR9 receptor. Eur Respir J. 2010;36(5):1143–54.
49. El Kebir D, József L, Pan W, Wang L, Filep JG. Bacterial DNA activates endothelial cells and promotes neutrophil adherence through TLR9 signaling. J Immunol. 2009;182(7):4386–94.
50. Means TK, Jones BW, Schromm AB, et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001;166(6):4074–82.
51. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13:816–25.
52. Albiger B, Dahlberg S, Henriques-Normark B, Normark S. Role of the innate immune system in host defence against bacterial infections: focus on the toll-like receptors. J Intern Med. 2007;261:511–28.
53. Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16(1):3–9.
54. Bean AG, Roach DR, Briscoe H, France MP, Korner H, Sedgwick JD, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. Immunology. 1999;162(6):3504–11.
55. Yamada H, Mizumo S, Horai R, Iwakura Y, Sugawara I. Protective role of interleukin-1 in mycobacterial infection in IL-1 alpha/beta double-knockout mice. Lab Investig. 2000;80(5):759–67.
56. Akira S. Toll-like receptor signaling. J Biol Chem. 2003;278(40):38105–8.
57. Jo EK. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs. Curr Opin Infect Dis. 2008;21(3):279–86.
58. Courtois G, Smahi A, Reichenbach J, et al. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest. 2003;112(7):1108–15.
59. Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet. 2001;27(3):277–85.
60. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299(5615):2076–9.
61. Bulut Y, Michelsen KS, Hayrapetian L, et al. Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem. 2005;280(22):20961–7.
62. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med. 2005;202(12):1715–24.
63. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011;30(1):16–34.
64. Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009;258:29–37.
65. Underhill DM, Ozinsky A, Smith KD, Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A. 1999;96(25):14459–63.
66. Kleinnijenhuis J, Joosten LA, van de Veerdonk FL, Savage N, van Crevel R, Kullberg BJ, et al. Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis. Eur J Immunol. 2009;39(7):1914–22.
67. Pompei L, Jang S, Zamlynny B, et al. Disparity in IL-12 release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to use of distinct TLRs. J Immunol. 2007;178(8):5192–9.
68. Drennan MB, Nicolle D, Quesniaux VJF, et al. Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection. Am J Pathol. 2004;164:49–57.
69. Reiling N, Hölscher C, Fehrenbach A, et al. Cutting edge: toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol. 2002;169(7):3480–4.
70. Quesniaux V, Fremond C, Jacobs M, Parida S, Nicolle D, Yeremeev V, et al. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 2004;6(10):946–59.
71. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutantmice. Infect Immun. 1997;65:4843–9.
72. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011;2011:405310.
73. Sugawara I, Yamada H, Li C, Mizuno S, Takeuchi O, et al. Mycobacterial infection in TLR2 and TLR6 knockout mice. Microbiol Immunol. 2003;47:327–36.
74. Abel B, Thieblemont N, Quesniaux VJ, Brown N, Mpagi J, et al. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol. 2002;169:3155–62.
75. Fremond CM, Togbe D, Doz E, Rose S, Vasseur V, Maillet I, et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J Immunol. 2007;179(2):1178–89.
76. Fremond CM, Yeremeev V, Nicolle DM, Jacobs M, Quesniaux VF, Ryffel B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest. 2004;114(12):1790–9.
77. Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun. 2004;4:2400–4.
78. Lee HM, Shin DM, Kim KK, Lee JS, Paik TH, Jo EK. Roles of reactive oxygen species in CXCL8 and CCL2 expression in response to the 30-kDa antigen of Mycobacterium tuberculosis. J Clin Immunol. 2009;29(1):46–56.
79. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol. 1999;163:3920–7.
80. Branger J, Knapp S, Weijer S, Leemans JC, Pater JM, Speelman P, et al. Role of Toll-like receptor 4 in Gram-positive and Gram-negative pneumonia in mice. Infect Immun. 2004;72:788–94.
81. Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med. 2003;9:525–32.
82. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, et al. Hyporesponsiveness to vaccination with BorreliaburgdorferiOspA in humans and in TLR1- and TLR2- deficient mice. Nat Med. 2002;8:878–84.
83. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25:187–91.
84. Kang TJ, Lee SB, Chae GT. A polymorphism in the Toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine. 2002;20:56–62.
85. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun. 2000;68:6398–401.
86. Fenhalls G, Squires GR, Stevens-Muller L, Bezuidenhout J, Amphlett G, Duncan K, et al. Associations between Toll-like receptors and interleukin-4 in the lungs of patients with tuberculosis. Am J Respir Cell Mol Biol. 2003;29:28–38.
87. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, et al. Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol. 2002;169:3480–4.
88. Kamath AB, Alt J, Debbabi H, Behar SM. Toll-like receptor 4-defective C3H/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis. Infect Immun. 2003;71:4112–8.
89. Rook GA, Dheda K, Zumla A. Opinion: immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol. 2005;5:661–7.
90. Davila S, Hibberd ML, HariDass R, Wong HE, Sahiratmadja E, Bonnard C, et al. Genetic association and expression studies indicate a role of Toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet. 2008;4:e1000218.
91. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009;388(4):621–5.
92. Songane M, Kleinnijenhuis J, Netea MG, van Crevel R. The role of autophagy in host defence against Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2012;92(5):388–96.
93. Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J. 2004;23:219–23.
94. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immunol. 2007;8:422–8.
95. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, et al. Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet. 2010;127:65–73.
96. Yim JJ, Lee HW, Lee HS, Kim YW, Han SK, et al. The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immunol. 2006;7:150–5.
97. Zhang Y, Jiang T, Yang X, Xue Y, Wang C, Liu J, et al. Toll-like receptor-1, -2, and -6 polymorphisms and pulmonary tuberculosis susceptibility: a systematic review and meta-analysis. PLoS One. 2013;8(5):e63357.
98. Biswas D, Gupta SK, Sindhwani G, Patras A. TLR2 polymorphisms, Arg753Gln and Arg677Trp, are not associated with increased burden of tuberculosis in Indian patients. BMC Res Notes. 2009;2:162.
99. Ma MJ, Xie LP, Wu SC, Tang F, Li H, et al. Toll-like receptors, tumor necrosis factor-alpha, and interleukin-10 gene polymorphisms in risk of pulmonary tuberculosis and disease severity. Hum Immunol. 2010;71:1005–10.
100. Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha VV. Toll like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis. 2010;90:306–10.
101. Xue Y, Zhao ZQ, Wang HJ, Jin L, Liu CP, et al. Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis. Int J Immunogenet. 2010;37:135–8.
102. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007;39:523–8.
103. Najmi N, Kaur G, Sharma SK, Mehra NK. Human Toll-like receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens. 2010;76:102–9.
104. Newport MJ, Allen A, Awomoyi AA, Dunstan SJ, McKinney E, et al. The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia. Tuberculosis (Edinb). 2004;84:347–52.
105. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66107.
106. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol. 1993;150(5):1804–12.
107. Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992;267(31):22190–7.
108. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine. 2003;21 Suppl 2:S43–7.
109. Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, et al. Cloning of mouse ptx3, a new member of the pentraxingene family expressed at extrahepatic sites. Blood. 1996;87(5):1862–72.
110. Lee GW, Goodman AR, Lee TH, Vilcek J. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol. 1994;153(8):3700–7.
111. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem. 1997;272(52):32817–23.
112. Garlanda C, Hirsch E, Bozza S, Salustri A, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420(6912):182–6.
113. Souza DG, Soares AC, Pinho V, et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol. 2002;160:1755–65.
114. Vouret-Craviari V, Matteucci C, Peri G, Poli G, Introna M, Mantovani A. Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect Immun. 1997;65(4):1345–50.
115. Olesen R, Wejse C, Velez DR, Bisseye C, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immunol. 2007;8(6):456–67.
116. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, Peri G, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005;7(1):1–8.
117. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675–80.
118. de Kluijver J, Grünberg K, Pons D, de Klerk EP, Dick CR, Sterk PJ, et al. Interleukin-1b and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. Clin Exp Allergy. 2003;33:1415–8.
119. Nakae S, Komiyama Y, Yokoyama H, Nambu A, Umeda M, Iwase M, et al. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol. 2003;15(4):483–90.
120. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, et al. The NLR gene family: a standard nomenclature. Immunity. 2008;28(3):285–7.
121. Fietta P, Delsante G. The inflammasomes: the key regulators of inflammation. Riv Biol. 2009;102(3):365–84.
122. Koo IC, Wang C, Raghavan S, Morisaki JH, Cox JS, et al. ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection. Cell Microbiol. 2008;10:1866–78.
123. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007;7:31–40.
124. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26.
125. Castaño D, Barrera LF, Rojas M. Mycobacterium tuberculosis alters the differentiation of monocytes into macrophages in vitro. Cell Immunol. 2011;268(2):60–7.
126. Mayer-Barber KD, Barber DL, Shenderov K, et al. Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol. 2010;184(7):3326–30.
127. Mishra BB, Moura-Alves P, Sonawane A, Hacohen N, Griffiths G, et al. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol. 2010;12:1046–63.
128. Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe. 2008;3:224–32.
129. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–50.
130. Shi S, Blumenthal A, Hickey CM, Gandotra S, Levy D, Ehrt S. Expression of many immunologically important genes in Mycobacterium tuberculosis-infected macrophages is independent of both TLR2 and TLR4 but dependent on IFN-alphabeta receptor and STAT1. J Immunol. 2005;175:3318–28.
131. Schneider BE, Korbel D, Hagens K, Koch M, Raupach B, Enders J, et al. A role for IL-18 in protective immunity against Mycobacterium tuberculosis. Eur J Immunol. 2010;40(2):396–405.